To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
Karim Fizazi
MD, PhD
University of Paris Saclay, Centre Oscar Lambret, Lille, France
GETUG President
Faculty
Daniel George
MD
Duke University School of Medicine, Durham, North Carolina
Eleanor Easley Distinguished Chair, Professor of Medicine, Surgery and Urology
Duke Cancer Institute, Durham, North Carolina
ACS Research Professor, Co-Lead, DCI Center for Prostate and Urologic Cancers
Moderator
Elisabeth I Heath
MD, FACP
Mayo Clinic, Rochester, Minnesota
Chair, Department of Oncology, Professor of Oncology
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of prostate cancer.
LEARNING OBJECTIVES
- Appreciate the incidence and clinical relevance of PTEN deficiency in prostate cancer, and develop an understanding of the optimal method to assess PTEN status in patients.
- Assess the clinical and biological factors in the selection of therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in order to optimally personalize treatment recommendations.
- Evaluate available Phase III data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency, and consider the potential role of this form of treatment.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video and fill out the evaluation.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Prof Fizazi — Honoraria, Former Institution: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc. Dr George — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Candel Therapeutics, Convergent Therapeutics Inc, Dendreon Pharmaceuticals LLC, Johnson & Johnson, Merck, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Johnson & Johnson, Novartis, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc, pharmaand GmbH; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Stock Options/Stock — Public Companies: Bristol Myers Squibb, Pfizer Inc; Nonrelevant Financial Relationships: IDEOlogy Health, MJH Life Sciences, Onclive, Targeted Oncology.
CONSULTING CLINICAL INVESTIGATORS — Neeraj Agarwal, MD, FASCO has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Rana R McKay, MD, FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Research and Development, K36 Therapeutics, Merck, MSD, Mirati Therapeutics Inc, Modra Pharmaceuticals, Novartis, Oncolys Biopharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Roche Laboratories Inc, Seagen Inc; Presenter/Co-Moderator: Curio Science; Speakers Bureaus: Sanofi; Steering Committees (Uncompensated): ORIC Pharmaceuticals; Travel Support: AstraZeneca UK; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines.
MODERATOR
Dr Heath — Advisory Committees: (Personal Compensation): AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, EMD Serono Inc, Gilead Sciences Inc, Novartis, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (Personal Compensation): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Novartis, Sanofi; Consulting Agreements (to Institution): AstraZeneca UK, Novartis; Contracted Research (Grants): K36 Therapeutics, Novartis; Contracted Research (Research Support to Institution): Amgen Inc, Arvinas, Astellas, AstraZeneca
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Release date: August 2026
Expiration date: August 2027
de Bono J et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur Urol 2025;87(6):672-82. Abstract
Fizazi K et al. A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. ESMO 2025;Abstract 2383O.
George DJ et al. Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Genitourinary Cancers Symposium 2026;Abstract 14.
Iyengar NM et al. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: Expert opinion. NPJ Breast Cancer 2025;12(1):16. Abstract
Kisiel F et al. Prognostic significance of PTEN loss in prostate cancer: A meta-analysis of Gleason grade and clinical outcomes. Cancers (Basel) 2025;17(17):2862. Abstract
Lotan T et al. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol 2016;29(8):904-14. Abstract
Maylin ZR et al. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells 2024;13(23):1999. Abstract
Sweeney C et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2021;398(10295):131-42. Abstract
Tortorella E et al. AR and PI3K/AKT in prostate cancer: A tale of two interconnected pathways. Int J Mol Sci 2023;24(3):2046. Abstract